Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 217, Issue 5, Pages 785-789Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jix610
Keywords
hepatitis E virus; viral hepatitis; HEV seroprevalence; Uganda; Rakai
Categories
Funding
- United States National Institutes of Health
- Division of Intramural Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health
- National Institute on Drug Abuse [T32-DA-007292]
- National Institute of Allergy and Infectious Diseases [R01-AI-16078, R01-AI-34826, R01-AI-34265]
- American Cancer Society [MRSG-07-284-01-CCE]
- National Institute of Child and Health Development [5P30-HD-06826]
- President's Emergency Fund for AIDS Relief
- Department of the Army, United States Army Medical Research and Material Command [DAMD17-98-2-8007]
Ask authors/readers for more resources
A cross-sectional study was conducted of 500 human immunodeficiency virus (HIV)-infected adults frequency matched on age, sex, and community to 500 HIV-uninfected individuals in the Rakai District, Uganda to evaluate seroprevalence of anti-hepatitis E virus (HEV) IgG antibodies. HEV seroprevalence was 47%, and 1 HIV-infected individual was actively infected with a genotype 3 virus. Using modified Poisson regression, male sex (prevalence ratios [PR] = 1.247; 95% confidence interval [CI], 1.071-1.450) and chronic hepatitis B virus infection (PR = 1.377; 95% CI, 1.090-1.738) were associated with HEV seroprevalence. HIV infection status (PR = 0.973; 95% CI, 0.852-1.111) was not associated with HEV seroprevalence. These data suggest there is a large burden of prior exposure to HEV in rural Uganda.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
